OIPE
SEP 07 2006
PATENT & TRADEMARK OFFICE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re U.S. Patent No.: 7,090,703)
)
Inventors: Stephane SABELLE)
)
Issue Date.: August 15, 2006)
)
For: PARA-PHENYLENEDIAMINE)
        DERIVATIVES COMPRISING A)
        CYCLIC DIAZA GROUP)
        SUBSTITUTED WITH A CATIONIC)
        RADICAL, AND USE OF THESE)
        DERIVATIVES FOR DYEING)
        KERATIN FIBERS)

Certificate
SEP 1 2 2006
of Correction

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

REQUEST FOR CERTIFICATE OF CORRECTION

Pursuant to 35 U.S.C. § 255, and 37 C.F.R. § 1.323, this is a request for a

Certificate of Correction in the above-identified patent. The mistakes identified in the

appended Form are of a clerical or typographical nature, and resulted from errors made

in good faith by both the Patent Office and the patentee. A check in the amount of $100

(the fee set forth in 37 C.F.R. § 1.20(a)) is attached. Should a check not be appended

or should any additional fees be needed, authorization is hereby given to charge any

fees due in connection with the filing of this request to Deposit Account No. 06-0916.

Two (2) copies of PTO Form 1050 are appended. The complete Certificate of

Correction involves three (3) pages. Issuance of the Certificate of Correction containing

the correction is earnestly requested.

SEP 13 2006

Please charge any required fees not included herewith to our Deposit Account

No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: September 7, 2006   By:_____

Thalia V. Warnement
Reg. No. 39,064

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO.   US 7,090,703 B2   Page 1 of 3

APPLICATION NO.: 10,807,162

ISSUE DATE: August 15, 2006

INVENTOR(S):   Stephane SABELLE

   It is hereby certified that an error or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In claim 1, column 33, line 8, "a aminoalkyl" should read --an aminoalkyl--.

In claim 1, column 33, line 31, "a aminoalkyl" should read --an aminoalkyl--.

In claim 10, column 35, lines 46-52,

should read

In claim 29, column 39, lines 50-52, "3-{2-[4-(4-Amino-phenyl)[1,4]diazepan-1-yl]propyl}-trimethylammonium chloride" should read --{3-[4-(4-Amino--phenyl)[1,4]diazepan-1-yl]propyl}trimethylammonium chloride--.

In claim 29, column 40, lines 51-54, "{3-[4-(4-Amino-phenyl)[1,4]diazepan-1-yl]ethyl}dimethyl(ethyl-2-methyl-3H-imidazol-1-ium chloride)ammonium; chloride"

should read --{3-[4-(4-Amino-phenyl)[1,4]diazepan-1-yl]ethyl}dimethyl(ethyl-2-methyl-3H-imidazol-1-ium chloride)ammonium chloride--.

In claim 29, column 41, lines 20-23, "{2-[4-(4-Amino-phenyl)[1,4]diazepan-1-yl]ethyl}dimethyl-(3-trimethylsilanyl-propyl)ammonium; chloride" should read --{2-[4-(4-Amino-phenyl)[1,4]diazepan-1-yl]ethyl}dimethyl-(3-trimethylsilanylpropyl)ammonium chloride--.

In claim 29, column 41, lines 36-39, "3-{2-[4-(4-Amino-phenyl)[1,4]diazepan-1-yl]ethyl}-1-(3-trimethylsilanyl-propyl)-3H-imidazol-1-ium chloride" should read --3-{2-[4-(4-Amino-phenyl)[1,4]diazepan-1-yl]ethyl}-1-(3-trimethylsilanylpropyl)-3H-imidazol-1-ium chloride--.

In claim 29, column 42, lines 52-54, "{3-{4-(4-Amino-3-methylphenyl)[1,4]-diazepan-1-yl]-propyl}-1-methyl-3H-imidazol-1-ium chloride" should read --3-{2-[4-(4-Amino-3-methylphenyl)[1,4]-diazepan-1-yl]propyl}-1-methyl-3H-imidazol-1-ium chloride--.

In claim 29, column 43, lines 35-37, "1-{3-[4-(4-Amino-3-methylphenyl)[1,4]diazepan-1-yl]propyl}-1-methyl-pyrrolidinium; chloride" should read --1-{3-[4-(4-Amino-3-methylphenyl)[1,4]diazepan-1-yl]propyl}-1-methylpyrrolidinium chloride--.

In claim 29, column 44, lines 20-22, "{3-[4-(4-Amino-phenyl)[1,4]diazepan-1-yl]-2-hydroxy-propyl}trimethylammonium; chloride" should read --{3-[4-(4-Amino-phenyl)[1,4]diazepan-1-yl]-2-hydroxypropyl}trimethylammonium chloride--.

In claim 29, column 44, lines 36-38, "{3-[4-(4-Amino-methylphenyl)[1,4-diazepan-1-yl]-2-hydroxypropyl}trimethylammonium; chloride" should read --{3-[4-(4-Amino-3-methylphenyl)[1,4-diazepan-1-yl]-2-hydroxypropyl}trimethylammonium chloride--.

In claim 29, column 45, lines 51-53, "3-{2-[4-(4-Amino-3-phenyl)piperazin-1-yl]ethyl}-1-methyl-3H-imidazol-1-ium chloride" should read --3-{2-[4-(4-Amino-phenyl)piperazin-1-yl]ethyl}-1-methyl-3H-imidazol-1-ium chloride--.

In claim 29, column 46, lines 1-3, "{3-[4-(4-Amino-3-phenyl)piperazin-1-yl]propyl}trimethylammonium chloride" should read --{3-[4-(4-Amino-phenyl)piperazin-1-yl]propyl}trimethylammonium chloride--.

In claim 29, column 46, lines 34-36, "{3-[4-(4-Amino-3-methylphenyl)piperazin-1-yl]-propyl}trimethylammonium chloride" should read --{3-[4-(4-Amino-3-methylphenyl)piperazin-1-yl]propyl}trimethylammonium chloride--.

In claim 29, column 47, lines 3-5, "1-{3-[4-(4-Amino-3-phenyl)piperazin-1-yl]propyl}-1-methylpyrrolidinium chloride" should read --1-{3-[4-(4-Amino-3-methylphenyl)piperazin-1-yl]propyl}-1-methylpyrrolidinium chloride--.

MAILING ADDRESS OF SENDER

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

SEP 13 2006

In claim 30, column 48, line 7, "a aminoalkyl" should read --an aminoalkyl--.

In claim 30, column 48, line 30, "a aminoalkyl" should read --an aminoalkyl--.

In claim 31, column 49, line 29, "a aminoalkyl" should read --an aminoalkyl--.

In claim 31, column 49, line 53, "a aminoalkyl" should read --an aminoalkyl--.

In claim 37, column 51, line 13, "a aminoalkyl" should read --an aminoalkyl--.

In claim 37, column 51, line 41, "a aminoalkyl" should read --an aminoalkyl--.

In claim 40, column 52, line 53, "a aminoalkyl" should read --an aminoalkyl--.

In claim 40, column 53, line 10, "a aminoalkyl" should read --an aminoalkyl--.

MAILING ADDRESS OF SENDER

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413